- Knopp Biosciences, a Pittsburgh, PA-based drug discovery and development company, completed a Series C equity financing of approximately $14m
- The round was led by Solas BioVentures, whose managing director, C. David Adair, M.D., elected to the Knopp Board of Managers
- Then the company is directing capital to a Phase 2 trial of oral dexpramipexole in moderate-to-severe eosinophilic asthma, with topline data expected in 1Q of 2021
- Knopp Biosciences is a drug discovery and development company also focused on delivering breakthrough treatments for immunological
- Its clinical-stage oral small molecule, dexpramipexole, is in Phase 2 clinical trials in moderate-to-severe eosinophilic asthma
- The Class C closing follows an equity financing of $13 million closed in 2019
